Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) recommended Ezmekly (mirdametinib) as a treatment option for symptomatic, inoperable plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) in children and young people aged 2 to 17 years, the UK subsidiary of German pharma Merck KGaA announced today. 4 September 2026
Related News
Insights
Company Spotlight
A South Korean biotechnology company developing next-generation biobetters and biosimilars through proprietary platform technologies, with its human hyaluronidase ALT-B4 attracting a growing roster of global pharmaceutical partners.
Latest News & Features of interest to Merck KGaA
Biotechnology
The European Commission (EC) has approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, Anglo-Swedish firm AstraZeneca and its Japanese partner Daiichi Sankyo announced. 1 September 2026
Pharmaceutical
Australia’s Therapeutic Goods Administration (TGA) has approved an updated indication for UK pharma major AstraZeneca’s Truqap (capivasertib) following evaluation of additional clinical data submitted after the medicine's initial registration. 1 September 2026
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca and Hong Kong-based biopharmaceutical firm HUTCHMED have reported positive top-line results from a Phase III study of their all-oral lung cancer combination in previously untreated patients in China, opening a route into the first-line setting. 1 September 2026
Generics
RedHill Biopharma on Monday announced the divestment of its 70% stake in the Talicia business to a subsidiary of Apotex Health for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones. 1 September 2026
Biotechnology
US biotech major Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. 1 September 2026
Biotechnology
German pharma major Bayer’s wholly-owned and independently operated subsidiary AskBio has announced the presentation of baseline participant characteristics from GenePHIT, one of the largest randomized gene therapy trials conducted in heart failure to date. 1 September 2026
Biotechnology
Significant research news last week included Regenxbio suffering a further setback in the development of RGX-121, with the US Food and Drug Administration (FDA) putting a clinical hold on its clinical trial. The FDA approved Jazz Pharmaceuticals and Zymeworks partnered cancer drug Ziihera for new indications, and Revolution Medicines won FDA approval for its Rasonque for the treatment pf pancreatic cancer. On the deal-making front, Biohaven granted a global license for its opakalim to South Korea’s SK Biopharmaceutical that could earn it $795 million. 30 August 2026
Pharmaceutical
Japan’s largest drugmaker Takeda announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. 29 August 2026
Biotechnology
China-based biotech DualityBio today announced that it has entered into a collaboration and license agreement with Genentech, a Roche subsidiary, to develop next-generation antibody-drug conjugates (ADCs) built on the company's proprietary DualityBio Unique Payload Antibody Conjugate (DUPAC) platform. 28 August 2026
Pharmaceutical
Israel-based Teva Pharmaceutical Industries German subsidiary today announced a bid to acquire an innovative neuroscience product from BioXcel Therapeutics, through a court-supervised sale process, sending the latter’s shares plummeting 66% to $0.24 in pre-market activity. 28 August 2026
Latest In Brief for Merck KGaA
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze